- Home
- TZOO vs ESLA Comparison
TZOO vs ESLA Comparison
Compare TZOO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TZOO | ESLA |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 60.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TZOO | ESLA |
|---|---|---|
| Price | $5.44 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.67 | $8.00 |
| AVG Volume (30 Days) | 170.4K | ★ 401.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.57 | N/A |
| Revenue Next Year | $17.03 | N/A |
| P/E Ratio | $8.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $0.73 |
| 52 Week High | $21.45 | $3.15 |
Technical Indicators
Market Signals| Indicator | TZOO | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 50.74 |
| Support Level | $5.28 | $1.14 |
| Resistance Level | $5.57 | $1.33 |
| Average True Range (ATR) | 0.26 | 0.19 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 21.95 | 53.64 |
Price Performance
Historical ComparisonAbout TZOO Travelzoo
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.